An observational study in Osteopenic Women and Proximal Femur Fracture, sponsored by AgNovos Healthcare, LLC. Completed. Open to female participants aged 56 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by AgNovos Healthcare, LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of Osteoporotic Patients". Performance will be evaluated via medical history evaluation, X-ray, DXA, CT and mobility testing.
The study will look at the extent to which the benefits demonstrated in the initial, baseline study were sustained over time. In this manner, it may be possible to determine the rate of change in BMD following the treatment; thereby allowing prediction of the total benefit period. In addition, this longer period of observation allows for further evaluation of the safety profile of the material in osteoporosis patients.
This observational single arm study will be broken into two parts:
In the original study, subjects completed a twenty-four (24) month follow-up visit after receiving a unilateral hip injection with the device. The contralateral hip acted as the control. The purpose of the study was to determine the safety of the injection as well as the initial improvement in femoral bone density in a twenty-four (24) month period.
In this follow-up study the subjects, after signing the informed consent form, will complete a short medical history (focused on their osteoporosis management) and a mobility test.
Subjects will also undergo a DXA, X-ray and CT scans of both hips.
36 studies on the registry are indexed under Proximal Femoral Fractures; 6 are open to participants now.
This study's enrollment of 12 is below the median of 140 across 13 observational studies indexed under Proximal Femoral Fractures.
Browse Proximal Femoral Fractures studies →AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Females aged 56 or older and menses have ceased for at least one year. Subjects that were participants in the original study that signed a consent form, received treatment with AGN1 Femoral LOEP and completed the original study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bone Mineral Density
Bone mineral density (BMD) assessed by DXA scans (T-score ) of the treated hip compared to nontreated hip (femoral neck).
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bone mineral density (BMD) assessed by DXA scans (absolute value measurement) of the treated hip compared to nontreated hip (femoral neck).
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Percent change compared to baseline for the treated femoral neck measurement of BMD.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Percent change compared to baseline for the untreated femoral neck measurement of BMD.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the trabecular bone density.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the trabecular bone volume.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the cortical bone density.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the cortical bone volume.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of any qualitative observations compared to baseline CT scans.
Time frame: through study completion, an average of 30 days
Subject Interview
All osteoporosis related events (as defined by the Investigator) from the twenty-four (24) month follow-up visit to current point-in-time including fragility fractures, changes in mobility and medication reactions.
Time frame: through study completion, an average of 30 days
Subject Interview
All osteoporosis medication use including vitamins and supplements from the twenty-four (24) month follow-up visit to current point-in-time.
Time frame: through study completion, an average of 30 days
Subject Interview
Any physical activity/exercise program from the twenty-four (24) month follow-up visit to current point-in-time.
Time frame: through study completion, an average of 30 days
FRAX Index Risk Assessment
Comparative calculation of a FRAX index for hip fracture risk based on BMD data from the treatment and contralateral hip using pre-procedure data compared to current point-in-time.
Time frame: through study completion, an average of 30 days
No study locations are listed for this record.
Ran from Jan 2016 to primary completion in Feb 2016, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AgNovos Healthcare, LLC